Thymogen
Thymogen • Also called Thymogen Acetate
Thymogen appears in immune-support and anti-aging peptide catalogs, but FDA has identified thymogen as ineligible for use in human drug compounding under section 503A.
Current status
Restricted
Immune-related interest, with current federal compounding constraints still in play.
FDA category
Not on 503A bulks list
Can pharmacies compound this?
No
Reclassification expected?
Unclear
The current federal issue is not that thymogen is waiting in a favorable review queue. FDA has already treated it as lacking a qualifying 503A compounding basis.
Primary Use
Immune-related interest
Also searched as
Thymogen Acetate
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Dec 8, 2025
Current status signal recorded: FDA warning-letter posture identifies thymogen as ineligible for use in human drug compounding under section 503A..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Thymogen status changes
State-specific notes
California
Immune peptides without a qualifying federal basis face especially conservative sourcing.